
Asco 2022 – Enhertu asks, how low can you go?
Another strong readout could redefine how Her2-negative breast cancer is treated, though a declared victory in triple-negatives is less clear.

Clovis equity investors overlook two elephants
Rubraca has scored in an all-comers, first-line ovarian cancer maintenance setting, but Clovis has bigger problems.

What’s next for relatlimab?
The Lag3 inhibitor is now approved in melanoma, but Bristol looks unlikely to stop there in its search for a safer Yervoy.

Enhertu tightens its stranglehold
The Astra/Daiichi antibody-drug conjugate could eat into Roche’s breast cancer dominance, courtesy of a clinical hit in Her2-low disease.

The heat is on Gilead as Tropics readout nears
Trodelvy has a chance to score in a study designed to expand its use, but given Gilead’s R&D track record nothing is certain.

Esmo 2021 – Opdivo’s glimmer of hope in front-line head and neck cancer
The failed Checkmate-651 study hints at a survival benefit in some PD-L1 expressers, but will this be enough to file?